Lecaillon J B, Dubois J P, Soula G, Pichard E, Poltera A A, Ginger C D
Biopharmaceutical Research Centre, Laboratoires Ciba-Geigy, Rueil-Malmaison, France.
Br J Clin Pharmacol. 1990 Oct;30(4):629-33. doi: 10.1111/j.1365-2125.1990.tb03825.x.
Eleven male patients from Mali with Onchocerca volvulus infections received in random order a 1200 mg single oral dose of CGP 6140 after an overnight fast and after food intake. The concentrations of CGP 6140 and of its N-oxide metabolite, CGP 13231, were measured in plasma and urine. Mean (+/- s.d.) AUC CGP 6140 values were 67.0 +/- 10.8 mumol l-1 h in fed and 22.0 +/- 17.2 mumol l-1 h in fasting patients. The mean maximum concentrations (Cmax) in plasma +/- s.d. were 12.7 +/- 2.8 mumol l-1 in fed and 4.7 +/- 4.1 mumol l-1 in fasting patients. The median time to Cmax was 3 h in fed and 2 h in fasting patients. Mean (+/- s.d.) AUC of the N-oxide metabolite was 59.9 +/- 10.7 mumol l-1 h in fed and 23.4 +/- 16.2 mumol l-1 h in fasting patients. The urinary recovery was less than 0.5% of dose for CGP 6140 in both fed and fasting conditions. It was 30.1 +/- 11.5 and 11.4 +/- 8.0% of the dose for the N-oxide metabolite in fed and fasting conditions, respectively. Variability in plasma concentrations and urinary recovery of CGP 6140 and of the N-oxide metabolite was greater in fasted patients. The low solubility of CGP 6140 in aqueous solutions at neutral pH and its higher solubility at acidic pH might explain the increase in bioavailability after food intake. The administration of CGP 6140 after food intake is therefore recommended for an optimal systemic effect.
11名来自马里的感染了盘尾丝虫的男性患者在禁食过夜后和进食后,随机接受了1200毫克的CGP 6140单次口服剂量。测定了血浆和尿液中CGP 6140及其N - 氧化物代谢物CGP 13231的浓度。进食患者中CGP 6140的平均(±标准差)药时曲线下面积(AUC)值为67.0±10.8μmol·l⁻¹·h,禁食患者中为22.0±17.2μmol·l⁻¹·h。血浆中的平均最大浓度(Cmax)±标准差在进食患者中为12.7±2.8μmol·l⁻¹,在禁食患者中为4.7±4.1μmol·l⁻¹。达到Cmax的中位时间在进食患者中为3小时,在禁食患者中为2小时。N - 氧化物代谢物的平均(±标准差)AUC在进食患者中为59.9±10.7μmol·l⁻¹·h,在禁食患者中为23.4±16.2μmol·l⁻¹·h。在进食和禁食条件下,CGP 6140的尿回收率均低于剂量的0.5%。对于N - 氧化物代谢物,在进食和禁食条件下,尿回收率分别为剂量的30.1±11.5%和11.4±8.0%。禁食患者中CGP 6140及其N - 氧化物代谢物的血浆浓度和尿回收率的变异性更大。CGP 6140在中性pH的水溶液中溶解度低,而在酸性pH下溶解度较高,这可能解释了进食后生物利用度的增加。因此,建议进食后服用CGP 6140以获得最佳的全身效果。